Home/All Molecules/Serratiopeptidase

Serratiopeptidase Range

Comprehensive Serratiopeptidase portfolio for Franchise & Manufacturing.

Category
serratiopeptidase
Total Formulations
11
Available Forms
Tablets

Expand Your Business with Our Multiple Divisions


Browse Serratiopeptidase portfolio by Dosage Form


The Cafoli Advantage for PCD Franchise & Manufacturing

WHO-GMP Quality

Every Serratiopeptidase batch undergoes rigorous in-house and third-party testing, strictly adhering to WHO-GMP standards for efficacy and safety.

Quality Policy

Monopoly & Branding

Secure exclusive PCD franchise rights for your territory and benefit from our range of premium, marketing-driven product packaging.

Market Strategy

Sales Support

Enhance your sales with Cafoli’s complete kit of marketing materials, including visual aids, MR bags, catch covers, and product cards.

Marketing Tools

Serratiopeptidase PCD Pharma Franchise

Serratiopeptidase PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Serratiopeptidase PCD pharma franchise company offering a portfolio of 11 Serratiopeptidase formulations across tablets. Every batch is manufactured at DCGI-approved facilities and supplied to franchise partners with district-level monopoly rights, ready-to-use promotional inputs and dependable stock availability.

What is Serratiopeptidase?

Serratiopeptidase is a proteolytic enzyme originally isolated from Serratia species. It hydrolyses bradykinin, fibrin and other inflammatory mediators at the site of injury, and is used as an anti-inflammatory and anti-oedema adjunct rather than as an analgesic in its own right. The compound record can be reviewed on PubChem.

Therapeutic Applications

Post-operative and post-traumatic swelling, dental and maxillofacial surgery, sinusitis and otorhinolaryngological inflammation, and soft-tissue injury. It is used almost entirely in fixed-dose combination with NSAIDs such as diclofenac, aceclofenac or paracetamol.

Prescribed by: Orthopaedic surgeons, dental surgeons, ENT specialists and general surgeons are the leading prescribers of Serratiopeptidase combinations.

Why Serratiopeptidase is a High-Potential Molecule for Distributors

Serratiopeptidase travels with the analgesic prescription rather than competing with it, and that is what makes it commercially attractive: the NSAID-serratiopeptidase combination is close to a default in Indian orthopaedic, dental and ENT practice after surgery or injury. It raises the value of the pack over a plain NSAID while remaining affordable, and prescriptions are frequent and non-seasonal. For a distributor already carrying an analgesic range, adding eleven serratiopeptidase combination formulations is a low-friction way to lift value per prescription across the same prescriber base.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers its Serratiopeptidase franchise partners genuine monopoly rights for their allotted district or territory, products manufactured in WHO-GMP certified, DCGI-approved units, and complete promotional support — visual aids, MR bags, sample packs, product cards and doctor gifting. With 1000+ channel partners across India, on-time dispatch and transparent net rates, we make it straightforward to build a profitable Serratiopeptidase business in your region.

References

  1. PubChem – Serratiopeptidase compound record, US National Library of Medicine
  2. PubMed – clinical literature on Serratiopeptidase, NCBI

Aceclofenac in Modern Clinical Practice

Our formulations of Serratiopeptidase find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to:


FAQ about Serratiopeptidase in PCD Franchise

Start Your Serratiopeptidase Franchise with Cafoli Lifecare

Ready to take monopoly rights for Serratiopeptidase in your district? Talk to our franchise team for net rates, packing details and the current availability list. Call 9518447302 or email info@cafoli.in.

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions (FAQs)

Cafoli Lifecare offers 11 Serratiopeptidase formulations in tablets. The current list with packing and net rates is shared with registered franchise enquiries.

Yes. Monopoly rights for the Serratiopeptidase range are allotted district-wise on a first-come basis and are confirmed in your franchise agreement, so no other Cafoli partner sells the same brands in your territory.

Orthopaedic surgeons, dental surgeons, ENT specialists and general surgeons are the leading prescribers of Serratiopeptidase combinations.

In practice it is prescribed almost entirely in fixed-dose combination with an NSAID such as diclofenac, aceclofenac or paracetamol, as an anti-oedema adjunct after surgery, dental procedures and soft-tissue injury. Distributors therefore treat the serratiopeptidase range as a value-adding extension of their analgesic line rather than a standalone brand.

You need a valid Drug License and a GST registration in your name. Once these are shared along with your territory preference, the Serratiopeptidase franchise agreement and monopoly allotment can be processed.